The Clinical Burden
Despite advances in antimicrobial therapy, SAB remains associated with significant morbidity and mortality. These core metrics highlight the urgency of appropriate care.
30-Day Mortality
Remains high despite modern antibiotics, often due to comorbidities.
Recurrence Rate
Patients relapsing after initial treatment course.
Metastatic Foci
Develop complications like endocarditis or osteomyelitis.
Hospital Length
Median stay is significantly prolonged by SAB diagnosis.
Where is SAB Acquired?
Understanding the source helps empiric antibiotic selection. Healthcare-associated cases are rising.
MRSA vs. MSSA Impact
Methicillin-Resistant S. aureus (MRSA) presents distinct challenges compared to Methicillin-Susceptible (MSSA) strains.
The Power of Protocol
Adherence to evidence-based "bundles" significantly improves patient survival. A critical component is the Infectious Disease (ID) Consultation.
Impact of ID Consultation
Automatic ID consultation for SAB is one of the most powerful interventions available.
- ✓ Ensures correct antibiotic dosing
- ✓ Promotes source control (e.g., pulling lines)
- ✓ Mandates echocardiography
Treatment Duration Decision Path
Determine therapy duration based on "Complicated" vs. "Uncomplicated" criteria. This decision is critical to prevent relapse.
Uncomplicated SAB
- • No implanted prostheses/hardware
- • Follow-up blood cultures negative @ 2-4 days
- • Defervescence within 72 hours
- • No metastatic sites (Endocarditis excluded)
Complicated SAB
- • Positive follow-up blood cultures
- • Presence of prosthetic devices
- • Clinical signs of endocarditis
- • Metastatic infection (Bone, Joint, Lung)
Metastatic Risk Profile
S. aureus frequently seeds to distant sites. A thorough physical exam and imaging are mandatory.
Key Diagnostic Steps:
- Echocardiography: TTE for all; TEE if high risk.
- Repeat Cultures: Every 48-72h until clear.
- Source Control: Drain abscesses immediately.